HighVista Strategies LLC Purchases 12,899 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

HighVista Strategies LLC boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 32.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,107 shares of the company’s stock after buying an additional 12,899 shares during the quarter. Keros Therapeutics makes up about 1.0% of HighVista Strategies LLC’s holdings, making the stock its 29th biggest position. HighVista Strategies LLC owned about 0.13% of Keros Therapeutics worth $3,026,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. KBC Group NV lifted its stake in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Keros Therapeutics by 36.7% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares during the period. Arizona State Retirement System grew its position in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after buying an additional 1,130 shares in the last quarter. Finally, Algert Global LLC increased its stake in Keros Therapeutics by 10.6% during the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after acquiring an additional 1,505 shares during the period. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 1.7 %

Shares of KROS stock opened at $56.73 on Tuesday. The company has a market capitalization of $2.30 billion, a P/E ratio of -10.89 and a beta of 1.20. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00. The firm has a 50-day moving average price of $59.49 and a 200 day moving average price of $52.28.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.33) EPS. As a group, research analysts expect that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Scotiabank began coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Guggenheim assumed coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics presently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.